GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Oncology/Acupuncture in Cancer Care: JCO Oncology Practice | July 2026
21

Acupuncture in Cancer Care: JCO Oncology Practice | July 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated July 1, 2026

Introduction:

Cancer-related symptoms often persist despite guideline-based pharmacologic treatment, affecting quality of life throughout the cancer journey. This review summarizes the current evidence, safety considerations, and practical implementation of acupuncture as an integrative supportive care intervention in modern oncology practice.

Why was this article needed?

  • Many cancer-related symptoms remain inadequately controlled with medications alone.
  • Patients increasingly seek non-pharmacological supportive therapies.
  • Acupuncture has been incorporated into several oncology guidelines, yet clinical adoption remains limited.
  • Oncologists need practical guidance regarding patient selection, safety, and referral pathways.
  • Implementation challenges, including reimbursement and staffing, have limited widespread integration.

Key Takeaways:

  • Acupuncture has the strongest evidence for managing selected cancer-related symptoms, including chemotherapy-induced nausea and vomiting, cancer-related pain, aromatase inhibitor–associated arthralgia, chemotherapy-induced peripheral neuropathy, xerostomia, fatigue, vasomotor symptoms, anxiety, and sleep disturbances.
  • When delivered by oncology-trained acupuncture practitioners, treatment is generally safe, provided clinicians consider blood counts, anticoagulation, thrombocytopenia, neutropenia, surgical timing, implanted devices, lymphedema risk, metastatic bone disease, and active infections.
  • Successful integration into oncology practice requires multidisciplinary referral pathways, routine use of patient-reported outcomes, standardized safety protocols, trained personnel, and institutional support.
  • Acupuncture should be viewed as a complementary supportive therapy rather than a replacement for evidence-based cancer treatment, with the goal of improving symptom control and quality of life.
  • Although insurance coverage remains variable, flexible delivery models and institutional support can facilitate sustainable implementation within comprehensive cancer centers.

Clinical Impact:

This review provides a practical roadmap for integrating evidence-based acupuncture into routine oncology care. Appropriate referral of selected patients may reduce symptom burden, decrease reliance on medications, improve quality of life, and support a more holistic, patient-centered approach to cancer care.

Bottom Line:

Acupuncture is a safe, evidence-based supportive care intervention for selected cancer-related symptoms when performed by trained practitioners within a multidisciplinary oncology program. Careful patient selection, standardized safety assessment, and coordinated implementation are essential for maximizing benefit while maintaining patient safety.

Related Q&A

22

SBRT vs RFA for Oligometastatic Liver Disease: British Journal of Radiology | July 2026

Introduction: Local ablative therapy plays an important role in managing oligometastatic liver disease when surgical resection is not feasible. This review compares stereotactic body radiotherapy (SBRT) and percutaneous...

23

Neoadjuvant Gemcitabine–Cisplatin–Durvalumab for Borderline Resectable Cholangiocarcinoma: Annals of Surgical Oncology | July 2026

Introduction: Borderline resectable cholangiocarcinoma (CCA) carries a poor prognosis because many patients cannot undergo curative surgery. Following the approval of gemcitabine–cisplatin–durvalumab (GCD) in advanced biliary tract cancer, this...

24

dMMR/MSI-H in Locally Advanced Rectal Cancer: European Journal of Cancer | July 2026

Introduction: Immune checkpoint inhibitors have revolutionized the treatment of dMMR/MSI-H rectal cancer, but most patients worldwide continue to receive total neoadjuvant therapy (TNT) as standard care. This international...

25

Dual vs Single Immune Checkpoint Inhibitors in MSI-H/dMMR mCRC: ESMO Gastrointestinal Oncology | September 2026

Introduction: Immune checkpoint inhibitors (ICIs) are the standard first-line treatment for MSI-H/dMMR metastatic colorectal cancer (mCRC). In the absence of direct head-to-head trials, this reconstructed individual patient data...

26

Dual vs Single Immune Checkpoint Blockade in MSI-H Metastatic CRC: ESMO Open | July 2026

Introduction: Immune checkpoint inhibitors (ICIs) have transformed the treatment of microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) metastatic colorectal cancer (mCRC). While pembrolizumab and nivolumab are established treatment options, recent...

27

Three Decades of Progress in Neuroendocrine Liver Metastases: Annals of Surgery | July 2026

Introduction: Neuroendocrine liver metastases (NELM) are a major determinant of morbidity and mortality in patients with neuroendocrine neoplasms. Over the past three decades, advances in imaging, systemic therapies,...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer